Boehringer Ingelheim has concluded phase one of their localization effort aimed at manufacturing their innovative thrombolytic medicines in Russia: the first batches of Metalyse (tenectaplase) for acute heart attack treatment were produced at NPO Petrovax Pharm facilities.

By the end of 2019, the companies intend to complete the transfer of technologies and to launch full-cycle production of innovative thrombolytic medicines at Petrovax Pharm’s production facility in the Moscow Region.

Vladimir Potanin, the owner and founder of Interros Group, one of the largest private investment companies in Russia, has completed acquisition of a controlling stake in Petrovax Pharm. For more details please visit www.petrovax.com

Holding constituents Rambler Media and Afisha will be united within the framework of a single structure. The company will be built on the base of Rambler. The General Director of the joined company will be Nikolay Molibog, who previously held the post of General Director at Afisha. Dmitry Stepanov and Yekaterina Kruglova, until recently deputy general directors at Afisha, will take on the positions of Products Director and Managing Director, respectively.

ProfMedia Finance closed the books for the debut ruble bond issue on July 20. The issue is guaranteed by the parent company ProfMedia Limited. Nominal value of the issued bonds is RUB 3bln, maturity is 5 years (put option in 3 years). Semiannual coupon was set at 10.5% pa till put. Standard&Poors assigned a preliminary rating B+ to this issue. The issue was arranged by ZAO Raiffeisenbank and ZAO KB Citibank.